Search

Your search keyword '"Hartkopf, Andreas D"' showing total 535 results
Start Over Author "Hartkopf, Andreas D"
535 results on '"Hartkopf, Andreas D"'

1. Aberrant p53 immunostaining patterns in breast carcinoma of no special type strongly correlate with presence and type of TP53 mutations

Author

Armbruster, Hannes, Schotte, Tilman, Götting, Isabell, Overkamp, Mathis, Granai, Massimo, Volmer, Lea Louise, Bahlinger, Veronika, Matovina, Sabine, Koch, André, Dannehl, Dominik, Engler, Tobias, Hartkopf, Andreas D., Brucker, Sara Y., Bonzheim, Irina, Fend, Falko, Staebler, Annette, and Montes-Mojarro, Ivonne

Published
2024
Full Text
View/download PDF

2. Physical activity levels are positively related to progression-free survival and reduced adverse events in advanced ER+ breast cancer

Author

Zimmer, Philipp, Esser, Tobias, Lueftner, Diana, Schuetz, Florian, Baumann, Freerk T., Rody, Achim, Schneeweiss, Andreas, Hartkopf, Andreas D., Decker, Thomas, Uleer, Christoph, Stoetzer, Oliver J., Foerster, Frank, Schmidt, Marcus, Mundhenke, Christoph, Steindorf, Karen, Tesch, Hans, Jackisch, Christian, Fischer, Thomas, Hanson, Sven, Kreuzeder, Julia, Guderian, Gernot, Fasching, Peter A., and Bloch, Wilhelm

Published
2024
Full Text
View/download PDF

3. Susceptibility gene mutations in germline and tumors of patients with HER2-negative advanced breast cancer

Author

Fasching, Peter A., Hu, Chunling, Hart, Steven N., Ruebner, Matthias, Polley, Eric C., Gnanaolivu, Rohan D., Hartkopf, Andreas D., Huebner, Hanna, Janni, Wolfgang, Hadji, Peyman, Tesch, Hans, Uhrig, Sabrina, Ettl, Johannes, Lux, Michael P., Lüftner, Diana, Wallwiener, Markus, Wurmthaler, Lena A., Goossens, Chloë, Müller, Volkmar, Beckmann, Matthias W., Hein, Alexander, Anetsberger, Daniel, Belleville, Erik, Wimberger, Pauline, Untch, Michael, Ekici, Arif B., Kolberg, Hans-Christian, Hartmann, Arndt, Taran, Florin-Andrei, Fehm, Tanja N., Wallwiener, Diethelm, Brucker, Sara Y., Schneeweiss, Andreas, Häberle, Lothar, and Couch, Fergus J.

Published
2024
Full Text
View/download PDF

4. p53 and ovarian carcinoma survival: an Ovarian Tumor Tissue Analysis consortium study

Author

Köbel, Martin, Kang, Eun‐Young, Weir, Ashley, Rambau, Peter F, Lee, Cheng‐Han, Nelson, Gregg S, Ghatage, Prafull, Meagher, Nicola S, Riggan, Marjorie J, Alsop, Jennifer, Anglesio, Michael S, Beckmann, Matthias W, Bisinotto, Christiani, Boisen, Michelle, Boros, Jessica, Brand, Alison H, Brooks‐Wilson, Angela, Carney, Michael E, Coulson, Penny, Courtney‐Brooks, Madeleine, Cushing‐Haugen, Kara L, Cybulski, Cezary, Deen, Suha, El‐Bahrawy, Mona A, Elishaev, Esther, Erber, Ramona, Fereday, Sian, Group, AOCS, Fischer, Anna, Gayther, Simon A, Barquin‐Garcia, Arantzazu, Gentry‐Maharaj, Aleksandra, Gilks, C Blake, Gronwald, Helena, Grube, Marcel, Harnett, Paul R, Harris, Holly R, Hartkopf, Andreas D, Hartmann, Arndt, Hein, Alexander, Hendley, Joy, Hernandez, Brenda Y, Huang, Yajue, Jakubowska, Anna, Jimenez‐Linan, Mercedes, Jones, Michael E, Kennedy, Catherine J, Kluz, Tomasz, Koziak, Jennifer M, Lesnock, Jaime, Lester, Jenny, Lubiński, Jan, Longacre, Teri A, Lycke, Maria, Mateoiu, Constantina, McCauley, Bryan M, McGuire, Valerie, Ney, Britta, Olawaiye, Alexander, Orsulic, Sandra, Osorio, Ana, Paz‐Ares, Luis, Ramón y Cajal, Teresa, Rothstein, Joseph H, Ruebner, Matthias, Schoemaker, Minouk J, Shah, Mitul, Sharma, Raghwa, Sherman, Mark E, Shvetsov, Yurii B, Singh, Naveena, Steed, Helen, Storr, Sarah J, Talhouk, Aline, Traficante, Nadia, Wang, Chen, Whittemore, Alice S, Widschwendter, Martin, Wilkens, Lynne R, Winham, Stacey J, Benitez, Javier, Berchuck, Andrew, Bowtell, David D, dos Reis, Francisco J Candido, Campbell, Ian, Cook, Linda S, DeFazio, Anna, Doherty, Jennifer A, Fasching, Peter A, Fortner, Renée T, García, María J, Goodman, Marc T, Goode, Ellen L, Gronwald, Jacek, Huntsman, David G, Karlan, Beth Y, Kelemen, Linda E, Kommoss, Stefan, Le, Nhu D, and Martin, Stewart G

Subjects
Reproductive Medicine, Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Cancer, Rare Diseases, Ovarian Cancer, Clinical Research, Aetiology, 2.1 Biological and endogenous factors, Humans, Female, Tumor Suppressor Protein p53, Ovarian Neoplasms, Carcinoma, Ovarian Epithelial, Carcinoma, Endometrioid, ovarian cancer, high-grade serous carcinoma, endometrioid, clear cell, TP53, p53, prognosis, AOCS Group, Clinical sciences
Abstract

Our objective was to test whether p53 expression status is associated with survival for women diagnosed with the most common ovarian carcinoma histotypes (high-grade serous carcinoma [HGSC], endometrioid carcinoma [EC], and clear cell carcinoma [CCC]) using a large multi-institutional cohort from the Ovarian Tumor Tissue Analysis (OTTA) consortium. p53 expression was assessed on 6,678 cases represented on tissue microarrays from 25 participating OTTA study sites using a previously validated immunohistochemical (IHC) assay as a surrogate for the presence and functional effect of TP53 mutations. Three abnormal expression patterns (overexpression, complete absence, and cytoplasmic) and the normal (wild type) pattern were recorded. Survival analyses were performed by histotype. The frequency of abnormal p53 expression was 93.4% (4,630/4,957) in HGSC compared to 11.9% (116/973) in EC and 11.5% (86/748) in CCC. In HGSC, there were no differences in overall survival across the abnormal p53 expression patterns. However, in EC and CCC, abnormal p53 expression was associated with an increased risk of death for women diagnosed with EC in multivariate analysis compared to normal p53 as the reference (hazard ratio [HR] = 2.18, 95% confidence interval [CI] 1.36-3.47, p = 0.0011) and with CCC (HR = 1.57, 95% CI 1.11-2.22, p = 0.012). Abnormal p53 was also associated with shorter overall survival in The International Federation of Gynecology and Obstetrics stage I/II EC and CCC. Our study provides further evidence that functional groups of TP53 mutations assessed by abnormal surrogate p53 IHC patterns are not associated with survival in HGSC. In contrast, we validate that abnormal p53 IHC is a strong independent prognostic marker for EC and demonstrate for the first time an independent prognostic association of abnormal p53 IHC with overall survival in patients with CCC.

Published
2023

6. Comparative analysis of EpCAM high-expressing and low-expressing circulating tumour cells with regard to their clonal relationship and clinical value

Author

Franken, André, Kraemer, Annika, Sicking, Alicia, Watolla, Meike, Rivandi, Mahdi, Yang, Liwen, Warfsmann, Jens, Polzer, Bernhard M., Friedl, Thomas W. P., Meier-Stiegen, Franziska, Stoecklein, Nikolas H., Dayan, Davut, Riethdorf, Sabine, Mueller, Volkmar, Pantel, Klaus, Koch, André, Hartkopf, Andreas D., Krawczyk, Natalia, Ruckhaeberle, Eugen, Niederacher, Dieter, Fehm, Tanja, and Neubauer, Hans

Published
2023
Full Text
View/download PDF

7. Return of individual genomic research results within the PRAEGNANT multicenter registry study

Author

Huebner, Hanna, Ruebner, Matthias, Kurbacher, Christian, Hadji, Peyman, Hartkopf, Andreas D., Lux, Michael P., Huober, Jens, Uhrig, Sabrina, Taran, Florin-Andrei, Overkamp, Friedrich, Tesch, Hans, Häberle, Lothar, Lüftner, Diana, Wallwiener, Markus, Müller, Volkmar, Beckmann, Matthias W., Hein, Alexander, Belleville, Erik, Untch, Michael, Janni, Wolfgang, Fehm, Tanja N., Kolberg, Hans-Christian, Wallwiener, Diethelm, Brucker, Sara Y., Schneeweiss, Andreas, Ettl, Johannes, Fasching, Peter A., and Michel, Laura L.

Published
2023
Full Text
View/download PDF

9. Pembrolizumab in combination with nab-paclitaxel for the treatment of patients with early-stage triple-negative breast cancer – A single-arm phase II trial (NeoImmunoboost, AGO-B-041)

Author

Fasching, Peter A., Hein, Alexander, Kolberg, Hans-Christian, Häberle, Lothar, Uhrig, Sabrina, Rübner, Matthias, Belleville, Erik, Hack, Carolin C., Fehm, Tanja N., Janni, Wolfang, Hartmann, Arndt, Erber, Ramona, Theuser, Anna-Katharin, Brucker, Sara Y., Hartkopf, Andreas D., and Untch, Michael

Published
2023
Full Text
View/download PDF

10. Clinical and pathological associations of PTEN expression in ovarian cancer: a multicentre study from the Ovarian Tumour Tissue Analysis Consortium.

Author

Martins, Filipe Correia, Couturier, Dominique-Laurent, Paterson, Anna, Karnezis, Anthony N, Chow, Christine, Nazeran, Tayyebeh M, Odunsi, Adekunle, Gentry-Maharaj, Aleksandra, Vrvilo, Aleksandra, Hein, Alexander, Talhouk, Aline, Osorio, Ana, Hartkopf, Andreas D, Brooks-Wilson, Angela, DeFazio, Anna, Fischer, Anna, Hartmann, Arndt, Hernandez, Brenda Y, McCauley, Bryan M, Karpinskyj, Chloe, de Sousa, Christiani B, Høgdall, Claus, Tiezzi, Daniel G, Herpel, Esther, Taran, Florin Andrei, Modugno, Francesmary, Keeney, Gary, Nelson, Gregg, Steed, Helen, Song, Honglin, Luk, Hugh, Benitez, Javier, Alsop, Jennifer, Koziak, Jennifer M, Lester, Jenny, Rothstein, Joseph H, de Andrade, Jurandyr M, Lundvall, Lene, Paz-Ares, Luis, Robles-Díaz, Luis, Wilkens, Lynne R, Garcia, Maria J, Intermaggio, Maria P, Alcaraz, Marie-Lyne, Brett, Mary A, Beckmann, Matthias W, Jimenez-Linan, Mercedes, Anglesio, Michael, Carney, Michael E, Schneider, Michael, Traficante, Nadia, Pejovic, Nadja, Singh, Naveena, Le, Nhu, Sinn, Peter, Ghatage, Prafull, Erber, Ramona, Edwards, Robert, Vierkant, Robert, Ness, Roberta B, Leung, Samuel, Orsulic, Sandra, Brucker, Sara Y, Kaufmann, Scott H, Fereday, Sian, Gayther, Simon, Winham, Stacey J, Kommoss, Stefan, Pejovic, Tanja, Longacre, Teri A, McGuire, Valerie, Rhenius, Valerie, Sieh, Weiva, Shvetsov, Yurii B, Whittemore, Alice S, Staebler, Annette, Karlan, Beth Y, Rodriguez-Antona, Cristina, Bowtell, David D, Goode, Ellen L, Høgdall, Estrid, Candido Dos Reis, Francisco J, Gronwald, Jacek, Chang-Claude, Jenny, Moysich, Kirsten B, Kelemen, Linda E, Cook, Linda S, Goodman, Marc T, Fasching, Peter A, Crawford, Robin, Deen, Suha, Menon, Usha, Huntsman, David G, Köbel, Martin, Ramus, Susan J, Pharoah, Paul DP, and Brenton, James D

Subjects
Oncology & Carcinogenesis, Oncology and Carcinogenesis, Public Health and Health Services
Abstract

BackgroundPTEN loss is a putative driver in histotypes of ovarian cancer (high-grade serous (HGSOC), endometrioid (ENOC), clear cell (CCOC), mucinous (MOC), low-grade serous (LGSOC)). We aimed to characterise PTEN expression as a biomarker in epithelial ovarian cancer in a large population-based study.MethodsTumours from 5400 patients from a multicentre observational, prospective cohort study of the Ovarian Tumour Tissue Analysis Consortium were used to evaluate associations between immunohistochemical PTEN patterns and overall survival time, age, stage, grade, residual tumour, CD8+ tumour-infiltrating lymphocytes (TIL) counts, expression of oestrogen receptor (ER), progesterone receptor (PR) and androgen receptor (AR) by means of Cox proportional hazard models and generalised Cochran-Mantel-Haenszel tests.ResultsDownregulation of cytoplasmic PTEN expression was most frequent in ENOC (most frequently in younger patients; p value = 0.0001) and CCOC and was associated with longer overall survival in HGSOC (hazard ratio: 0.78, 95% CI: 0.65-0.94, p value = 0.022). PTEN expression was associated with ER, PR and AR expression (p values: 0.0008, 0.062 and 0.0002, respectively) in HGSOC and with lower CD8 counts in CCOC (p value

Published
2020

12. Neoadjuvant dynamic marker-adjusted personalized therapy comparing trastuzumab-deruxtecan versus pacli-/docetaxel + carboplatin + trastuzumab + pertuzumab in HER2+ early breast cancer: WSG-ADAPT-HER2-IV.

Author

Harbeck, Nadia, primary, Braun, Michael, additional, Gluz, Oleg, additional, Schmid, Peter, additional, Graeser, Monika Karla, additional, Hartkopf, Andreas D., additional, Hoffmann, Oliver, additional, Kostara, Athina, additional, Polata, Silke, additional, Volmer, Lea Louise, additional, von Schumann, Raquel, additional, Wetzig, Sarah, additional, Wiebe, Stefanie, additional, Zaiss, Matthias R., additional, Fischer, Lotta Ada, additional, Scheffen, Iris, additional, Christgen, Matthias, additional, Kreipe, Hans Heinrich, additional, Nitz, Ulrike, additional, and Kuemmel, Sherko, additional

Published
2024
Full Text
View/download PDF

13. Multiomic factor analysis for pathologic complete response (pCR) after 12 weeks of pembrolizumab + trastuzumab + pertuzumab in HER2-enriched (HER2-E) early breast cancer (eBC) in the Keyriched-1 trial.

Author

Graeser, Monika Karla, primary, Gluz, Oleg, additional, Schmid, Peter, additional, Jozwiak, Katarzyna, additional, Feuerhake, Friedrich, additional, Volk, Valery, additional, Ulbrich-Gebauer, Daniel, additional, Biehl, Claudia, additional, Reinisch, Mattea, additional, Luedtke-Heckenkamp, Kerstin, additional, Hartkopf, Andreas D., additional, Hilpert, Felix, additional, Braun, Michael, additional, Blohmer, Jens U., additional, Christgen, Matthias, additional, Kreipe, Hans Heinrich, additional, Nitz, Ulrike, additional, Pelz, Enrico, additional, Harbeck, Nadia, additional, and Kuemmel, Sherko, additional

Published
2024
Full Text
View/download PDF

14. Update Breast Cancer 2024 Part 1 – Expert Opinion on Advanced Breast Cancer

Author

Würstlein, Rachel, additional, Kolberg, Hans-Christian, additional, Hartkopf, Andreas D., additional, Fehm, Tanja N., additional, Welslau, Manfred, additional, Schütz, Florian, additional, Fasching, Peter A., additional, Janni, Wolfgang, additional, Witzel, Isabell, additional, Thomssen, Christoph, additional, Krückel, Annika, additional, Belleville, Erik, additional, Lüftner, Diana, additional, Untch, Michael, additional, Thill, Marc, additional, Hörner, Manuel, additional, Tesch, Hans, additional, Ditsch, Nina, additional, Lux, Michael P., additional, Aktas, Bahriye, additional, Banys-Paluchowski, Maggie, additional, Taran, Florin-Andrei, additional, Wöckel, Achim, additional, Harbeck, Nadia, additional, Stickeler, Elmar, additional, Bartsch, Rupert, additional, Schneeweiss, Andreas, additional, Ettl, Johannes, additional, Krug, David, additional, and Müller, Volkmar, additional

Published
2024
Full Text
View/download PDF

15. CDK4/6 Inhibition – Therapy Sequences and the Quest to Find the Best Biomarkers – an Overview of Current Programs

Author

Schneeweiss, Andreas, additional, Brucker, Sara Y., additional, Huebner, Hanna, additional, Volmer, Lea L., additional, Hack, Carolin C., additional, Seitz, Katharina, additional, Ruebner, Matthias, additional, Heublein, Sabine, additional, Thewes, Verena, additional, Lüftner, Diana, additional, Lux, Michael P., additional, Jurhasz-Böss, Ingolf, additional, Taran, Florin-Andrei, additional, Wimberger, Pauline, additional, Anetsberger, Daniel, additional, Beierlein, Milena, additional, Schmidt, Marcus, additional, Radosa, Julia, additional, Müller, Volkmar, additional, Janni, Wolfgang, additional, Rack, Brigitte, additional, Belleville, Erik, additional, Untch, Michael, additional, Thill, Marc, additional, Ditsch, Nina, additional, Aktas, Bahriye, additional, Nel, Ivonne, additional, Kolberg, Hans-Christian, additional, Engerle, Tobias, additional, Tesch, Hans, additional, Roos, Christian, additional, Budden, Christina, additional, Neubauer, Hans, additional, Hartkopf, Andreas D., additional, Fehm, Tanja N., additional, and Fasching, Peter A., additional

Published
2024
Full Text
View/download PDF

16. Attrition in the First Three Therapy Lines in Patients with Advanced Breast Cancer in the German Real-World PRAEGNANT Registry

Author

Hartkopf, Andreas D., primary, Walter, Christina B., primary, Kolberg, Hans-Christian, additional, Hadji, Peyman, additional, Tesch, Hans, additional, Fasching, Peter A., additional, Ettl, Johannes, additional, Lüftner, Diana, additional, Wallwiener, Markus, additional, Müller, Volkmar, additional, Beckmann, Matthias W., additional, Belleville, Erik, additional, Huebner, Hanna, additional, Uhrig, Sabrina, additional, Goossens, Chloë, additional, Link, Theresa, additional, Hielscher, Carsten, additional, Mundhenke, Christoph, additional, Kurbacher, Christian, additional, Wuerstlein, Rachel, additional, Untch, Michael, additional, Janni, Wolfgang, additional, Taran, Florin-Andrei, additional, Michel, Laura L., additional, Lux, Michael P., additional, Wallwiener, Diethelm, additional, Brucker, Sara Y., additional, Fehm, Tanja N., additional, Häberle, Lothar, additional, and Schneeweiss, Andreas, additional

Published
2024
Full Text
View/download PDF

18. Physical activity levels are positively related to progression-free survival and reduced adverse events in advanced ER+ breast cancer.

Author

Zimmer, Philipp, Esser, Tobias, Lueftner, Diana, Schuetz, Florian, Baumann, Freerk T., Rody, Achim, Schneeweiss, Andreas, Hartkopf, Andreas D., Decker, Thomas, Uleer, Christoph, Stoetzer, Oliver J., Foerster, Frank, Schmidt, Marcus, Mundhenke, Christoph, Steindorf, Karen, Tesch, Hans, Jackisch, Christian, Fischer, Thomas, Hanson, Sven, and Kreuzeder, Julia

Abstract

Background : Increased levels of physical activity are associated with a reduction of breast cancer mortality, especially in postmenopausal women with positive hormone receptor status. So far, previous observational case–control and cohort studies have focused on associations between overall leisure time physical activity and survival of women with breast cancer in general. Methods: In this multicenter prospective cohort study, conducted in Germany between 30th August 2012 to 29th December 2017, we investigated general physical activity in a homogenous sample of n = 1440 postmenopausal women with advanced (inoperable locally advanced or metastatic), hormone receptor-positive breast cancer receiving the same therapy (everolimus and exemestane). Self-reported physical activity was assessed using the Godin Leisure Time Exercise Questionnaire (GLTEQ) before and every 3 months during treatment. Participants were then classified into "active" and "insufficiently active" to screen their activity behavior the week prior to medical treatment. In addition, changes in physical activity patterns were assessed. Adjusted Cox regression analyses were performed for the activity categories to determine hazard ratios (HR). Besides progression-free survival (PFS), adverse events (AEs), QoL, and fatigue were assessed every 3 months until study termination. Results: Compared to "insufficiently active" patients, "active" individuals indicated a significantly longer PFS (HR: 0.84 [0.74; 0.984], p =.0295). No significant differences were observed for changes of physical activity behavior. Patients who reported to be "active" at baseline revealed significantly fewer AEs compared to "insufficiently" active patients. In detail, both severe and non-severe AEs occurred less frequently in the "active" patients group. In line with that, QoL and fatigue were better in physical "active" patients compared to their insufficient active counterparts at the last post-baseline assessment. Participants who remained or become active indicated less AEs, a higher QoL, and reduced fatigue levels. Conclusions: Physical activity behavior prior to medical treatment might have prognostic value in patients with advanced breast cancer in terms of extending the PFS. Moreover, physical activity before and during treatment may reduce treatment-related side effects and improve patients' QoL and fatigue. Trial registration: EUPAS9462. Registered 30th October 2012 "retrospectively registered." [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

20. Association of p16 expression with prognosis varies across ovarian carcinoma histotypes: an Ovarian Tumor Tissue Analysis consortium study.

Author

Rambau, Peter F, Vierkant, Robert A, Intermaggio, Maria P, Kelemen, Linda E, Goodman, Marc T, Herpel, Esther, Pharoah, Paul D, Kommoss, Stefan, Jimenez-Linan, Mercedes, Karlan, Beth Y, Gentry-Maharaj, Aleksandra, Menon, Usha, Polo, Susanna Hernando, Candido Dos Reis, Francisco J, Doherty, Jennifer Anne, Gayther, Simon A, Sharma, Raghwa, Larson, Melissa C, Harnett, Paul R, Hatfield, Emma, de Andrade, Jurandyr M, Nelson, Gregg S, Steed, Helen, Schildkraut, Joellen M, Carney, Micheal E, Høgdall, Estrid, Whittemore, Alice S, Widschwendter, Martin, Kennedy, Catherine J, Wang, Frances, Wang, Qin, Wang, Chen, Armasu, Sebastian M, Daley, Frances, Coulson, Penny, Jones, Micheal E, Anglesio, Micheal S, Chow, Christine, de Fazio, Anna, García-Closas, Montserrat, Brucker, Sara Y, Cybulski, Cezary, Harris, Holly R, Hartkopf, Andreas D, Huzarski, Tomasz, Jensen, Allan, Lubiński, Jan, Oszurek, Oleg, Benitez, Javier, Mina, Fady, Staebler, Annette, Taran, Florin Andrei, Pasternak, Jana, Talhouk, Aline, Rossing, Mary Anne, Hendley, Joy, AOCS Group, Edwards, Robert P, Fereday, Sian, Modugno, Francesmary, Ness, Roberta B, Sieh, Weiva, El-Bahrawy, Mona A, Winham, Stacey J, Lester, Jenny, Kjaer, Susanne K, Gronwald, Jacek, Sinn, Peter, Fasching, Peter A, Chang-Claude, Jenny, Moysich, Kirsten B, Bowtell, David D, Hernandez, Brenda Y, Luk, Hugh, Behrens, Sabine, Shah, Mitul, Jung, Audrey, Ghatage, Prafull, Alsop, Jennifer, Alsop, Kathryn, García-Donas, Jesús, Thompson, Pamela J, Swerdlow, Anthony J, Karpinskyj, Chloe, Cazorla-Jiménez, Alicia, García, María J, Deen, Susha, Wilkens, Lynne R, Palacios, José, Berchuck, Andrew, Koziak, Jennifer M, Brenton, James D, Cook, Linda S, Goode, Ellen L, Huntsman, David G, Ramus, Susan J, and Köbel, Martin

Subjects
AOCS Group, Ovary, Humans, Adenocarcinoma, Mucinous, Cystadenocarcinoma, Serous, Ovarian Neoplasms, Prognosis, Immunohistochemistry, Survival Rate, Adult, Aged, Middle Aged, Female, Cyclin-Dependent Kinase Inhibitor p16, RT-QPCR, immunocytochemistry, ovary, Adenocarcinoma, Mucinous, Cystadenocarcinoma, Serous, Cancer, Genetics, Ovarian Cancer, Rare Diseases, 2.1 Biological and endogenous factors
Abstract

We aimed to validate the prognostic association of p16 expression in ovarian high-grade serous carcinomas (HGSC) and to explore it in other ovarian carcinoma histotypes. p16 protein expression was assessed by clinical-grade immunohistochemistry in 6525 ovarian carcinomas including 4334 HGSC using tissue microarrays from 24 studies participating in the Ovarian Tumor Tissue Analysis consortium. p16 expression patterns were interpreted as abnormal (either overexpression referred to as block expression or absence) or normal (heterogeneous). CDKN2A (which encodes p16) mRNA expression was also analyzed in a subset (n = 2280) mostly representing HGSC (n = 2010). Association of p16 expression with overall survival (OS) was determined within histotypes as was CDKN2A expression for HGSC only. p16 block expression was most frequent in HGSC (56%) but neither protein nor mRNA expression was associated with OS. However, relative to heterogeneous expression, block expression was associated with shorter OS in endometriosis-associated carcinomas, clear cell [hazard ratio (HR): 2.02, 95% confidence (CI) 1.47-2.77, p < 0.001] and endometrioid (HR: 1.88, 95% CI 1.30-2.75, p = 0.004), while absence was associated with shorter OS in low-grade serous carcinomas (HR: 2.95, 95% CI 1.61-5.38, p = 0.001). Absence was most frequent in mucinous carcinoma (50%), and was not associated with OS in this histotype. The prognostic value of p16 expression is histotype-specific and pattern dependent. We provide definitive evidence against an association of p16 expression with survival in ovarian HGSC as previously suggested. Block expression of p16 in clear cell and endometrioid carcinoma should be further validated as a prognostic marker, and absence in low-grade serous carcinoma justifies CDK4 inhibition.

Published
2018

21. MyD88 and TLR4 Expression in Epithelial Ovarian Cancer.

Author

Block, Matthew S, Vierkant, Robert A, Rambau, Peter F, Winham, Stacey J, Wagner, Philipp, Traficante, Nadia, Tołoczko, Aleksandra, Tiezzi, Daniel G, Taran, Florin Andrei, Sinn, Peter, Sieh, Weiva, Sharma, Raghwa, Rothstein, Joseph H, Ramón Y Cajal, Teresa, Paz-Ares, Luis, Oszurek, Oleg, Orsulic, Sandra, Ness, Roberta B, Nelson, Gregg, Modugno, Francesmary, Menkiszak, Janusz, McGuire, Valerie, McCauley, Bryan M, Mack, Marie, Lubiński, Jan, Longacre, Teri A, Li, Zheng, Lester, Jenny, Kennedy, Catherine J, Kalli, Kimberly R, Jung, Audrey Y, Johnatty, Sharon E, Jimenez-Linan, Mercedes, Jensen, Allan, Intermaggio, Maria P, Hung, Jillian, Herpel, Esther, Hernandez, Brenda Y, Hartkopf, Andreas D, Harnett, Paul R, Ghatage, Prafull, García-Bueno, José M, Gao, Bo, Fereday, Sian, Eilber, Ursula, Edwards, Robert P, de Sousa, Christiani B, de Andrade, Jurandyr M, Chudecka-Głaz, Anita, Chenevix-Trench, Georgia, Cazorla, Alicia, Brucker, Sara Y, Australian Ovarian Cancer Study Group, Alsop, Jennifer, Whittemore, Alice S, Steed, Helen, Staebler, Annette, Moysich, Kirsten B, Menon, Usha, Koziak, Jennifer M, Kommoss, Stefan, Kjaer, Susanne K, Kelemen, Linda E, Karlan, Beth Y, Huntsman, David G, Høgdall, Estrid, Gronwald, Jacek, Goodman, Marc T, Gilks, Blake, García, María José, Fasching, Peter A, de Fazio, Anna, Deen, Suha, Chang-Claude, Jenny, Candido Dos Reis, Francisco J, Campbell, Ian G, Brenton, James D, Bowtell, David D, Benítez, Javier, Pharoah, Paul DP, Köbel, Martin, Ramus, Susan J, and Goode, Ellen L

Subjects
Australian Ovarian Cancer Study Group, Humans, Ovarian Neoplasms, Tissue Array Analysis, Immunohistochemistry, Survival Analysis, Adult, Aged, Middle Aged, Female, Toll-Like Receptor 4, Myeloid Differentiation Factor 88, Biomarkers, Tumor, Carcinoma, Ovarian Epithelial, Biomarkers, Tumor, Carcinoma, Ovarian Epithelial, Medical and Health Sciences
Abstract

ObjectiveTo evaluate myeloid differentiation primary response gene 88 (MyD88) and Toll-like receptor 4 (TLR4) expression in relation to clinical features of epithelial ovarian cancer, histologic subtypes, and overall survival.Patients and methodsWe conducted centralized immunohistochemical staining, semi-quantitative scoring, and survival analysis in 5263 patients participating in the Ovarian Tumor Tissue Analysis consortium. Patients were diagnosed between January 1, 1978, and December 31, 2014, including 2865 high-grade serous ovarian carcinomas (HGSOCs), with more than 12,000 person-years of follow-up time. Tissue microarrays were stained for MyD88 and TLR4, and staining intensity was classified using a 2-tiered system for each marker (weak vs strong).ResultsExpression of MyD88 and TLR4 was similar in all histotypes except clear cell ovarian cancer, which showed reduced expression compared with other histotypes (P

Published
2018

22. Dose-Response Association of CD8+ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer

Author

Goode, Ellen L, Block, Matthew S, Kalli, Kimberly R, Vierkant, Robert A, Chen, Wenqian, Fogarty, Zachary C, Gentry-Maharaj, Aleksandra, Tołoczko, Aleksandra, Hein, Alexander, Bouligny, Aliecia L, Jensen, Allan, Osorio, Ana, Hartkopf, Andreas D, Ryan, Andy, Chudecka-Głaz, Anita, Magliocco, Anthony M, Hartmann, Arndt, Jung, Audrey Y, Gao, Bo, Hernandez, Brenda Y, Fridley, Brooke L, McCauley, Bryan M, Kennedy, Catherine J, Wang, Chen, Karpinskyj, Chloe, de Sousa, Christiani B, Tiezzi, Daniel G, Wachter, David L, Herpel, Esther, Taran, Florin Andrei, Modugno, Francesmary, Nelson, Gregg, Lubiński, Jan, Menkiszak, Janusz, Alsop, Jennifer, Lester, Jenny, García-Donas, Jesús, Nation, Jill, Hung, Jillian, Palacios, José, Rothstein, Joseph H, Kelley, Joseph L, de Andrade, Jurandyr M, Robles-Díaz, Luis, Intermaggio, Maria P, Widschwendter, Martin, Beckmann, Matthias W, Ruebner, Matthias, Jimenez-Linan, Mercedes, Singh, Naveena, Oszurek, Oleg, Harnett, Paul R, Rambau, Peter F, Sinn, Peter, Wagner, Philipp, Ghatage, Prafull, Sharma, Raghwa, Edwards, Robert P, Ness, Roberta B, Orsulic, Sandra, Brucker, Sara Y, Johnatty, Sharon E, Longacre, Teri A, Eilber, Ursula, McGuire, Valerie, Sieh, Weiva, Natanzon, Yanina, Li, Zheng, Whittemore, Alice S, deFazio, Anna, Staebler, Annette, Karlan, Beth Y, Gilks, Blake, Bowtell, David D, Høgdall, Estrid, dos Reis, Francisco J Candido, Steed, Helen, Campbell, Ian G, Gronwald, Jacek, Benítez, Javier, Koziak, Jennifer M, Chang-Claude, Jenny, Moysich, Kirsten B, Kelemen, Linda E, Cook, Linda S, Goodman, Marc T, García, María José, Fasching, Peter A, Kommoss, Stefan, Deen, Suha, Kjaer, Susanne K, Menon, Usha, Brenton, James D, Pharoah, Paul DP, Chenevix-Trench, Georgia, Huntsman, David G, Winham, Stacey J, Köbel, Martin, and Ramus, Susan J

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Immunology, Cancer, Prevention, Vaccine Related, Rare Diseases, Clinical Research, Ovarian Cancer, BRCA2 Protein, CD8 Antigens, Carcinoma, Ovarian Epithelial, Cohort Studies, Cystadenocarcinoma, Serous, Female, Humans, Lymphocytes, Tumor-Infiltrating, Middle Aged, Mutation, Neoplasm Grading, Ovarian Neoplasms, Prospective Studies, Survival Analysis, Treatment Outcome, Ovarian Tumor Tissue Analysis (OTTA) Consortium, Public Health and Health Services, Oncology and carcinogenesis
Abstract

ImportanceCytotoxic CD8+ tumor-infiltrating lymphocytes (TILs) participate in immune control of epithelial ovarian cancer; however, little is known about prognostic patterns of CD8+ TILs by histotype and in relation to other clinical factors.ObjectiveTo define the prognostic role of CD8+ TILs in epithelial ovarian cancer.Design, setting, and participantsThis was a multicenter observational, prospective survival cohort study of the Ovarian Tumor Tissue Analysis Consortium. More than 5500 patients, including 3196 with high-grade serous ovarian carcinomas (HGSOCs), were followed prospectively for over 24 650 person-years.ExposuresFollowing immunohistochemical analysis, CD8+ TILs were identified within the epithelial components of tumor islets. Patients were grouped based on the estimated number of CD8+ TILs per high-powered field: negative (none), low (1-2), moderate (3-19), and high (≥20). CD8+ TILs in a subset of patients were also assessed in a quantitative, uncategorized manner, and the functional form of associations with survival was assessed using penalized B-splines.Main outcomes and measuresOverall survival time.ResultsThe final sample included 5577 women; mean age at diagnosis was 58.4 years (median, 58.2 years). Among the 5 major invasive histotypes, HGSOCs showed the most infiltration. CD8+ TILs in HGSOCs were significantly associated with longer overall survival; median survival was 2.8 years for patients with no CD8+ TILs and 3.0 years, 3.8 years, and 5.1 years for patients with low, moderate, or high levels of CD8+ TILs, respectively (P value for trend = 4.2 × 10−16). A survival benefit was also observed among women with endometrioid and mucinous carcinomas, but not for those with the other histotypes. Among HGSOCs, CD8+ TILs were favorable regardless of extent of residual disease following cytoreduction, known standard treatment, and germline BRCA1 pathogenic mutation, but were not prognostic for BRCA2 mutation carriers. Evaluation of uncategorized CD8+ TIL counts showed a near-log-linear functional form.Conclusions and relevanceThis study demonstrates the histotype-specific nature of immune infiltration and provides definitive evidence for a dose-response relationship between CD8+ TILs and HGSOC survival. That the extent of infiltration is prognostic, not merely its presence or absence, suggests that understanding factors that drive infiltration will be the key to unraveling outcome heterogeneity in this cancer.

Published
2017

23. Disseminated tumour cells from the bone marrow of early breast cancer patients: Results from an international pooled analysis

Author

Hartkopf, Andreas D., Brucker, Sara Y., Taran, Florin-Andrei, Harbeck, Nadia, von Au, Alexandra, Naume, Bjørn, Pierga, Jean-Yves, Hoffmann, Oliver, Beckmann, Matthias W., Rydén, Lisa, Fehm, Tanja, Aft, Rebecca, Solà, Montserrat, Walter, Vincent, Rack, Brigitte, Schuetz, Florian, Borgen, Elin, Ta, Minh-Hanh, Bittner, Ann-Kathrin, Fasching, Peter A., Fernö, Mårten, Krawczyk, Natalia, Weilbaecher, Katherine, Margelí, Mireia, Hahn, Markus, Jueckstock, Julia, Domschke, Christoph, Bidard, Francois-Clement, Kasimir-Bauer, Sabine, Schoenfisch, Birgitt, Kurt, Ayse G., Wallwiener, Markus, Gebauer, Gerhard, Klein, Christoph A., Wallwiener, Diethelm, Janni, Wolfgang, and Pantel, Klaus

Published
2021
Full Text
View/download PDF

25. Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer — Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany

Author

Schneeweiss, Andreas, Ettl, Johannes, Lüftner, Diana, Beckmann, Matthias W., Belleville, Erik, Fasching, Peter A., Fehm, Tanja N., Geberth, Matthias, Häberle, Lothar, Hadji, Peyman, Hartkopf, Andreas D., Hielscher, Carsten, Huober, Jens, Ruckhäberle, Eugen, Janni, Wolfgang, Kolberg, Hans Christian, Kurbacher, Christian M., Klein, Evelyn, Lux, Michael P., Müller, Volkmar, Nabieva, Naiba, Overkamp, Friedrich, Tesch, Hans, Laakmann, Elena, Taran, Florin-Andrei, Seitz, Julia, Thomssen, Christoph, Untch, Michael, Wimberger, Pauline, Wuerstlein, Rachel, Volz, Bernhard, Wallwiener, Diethelm, Wallwiener, Markus, and Brucker, Sara Y.

Published
2020
Full Text
View/download PDF

26. ENABLE: App-based digital capture and intervention of patientreported quality of life, adverse events, and treatment satisfaction in breast cancer - study protocol for a randomized controlled trial

Author

Deutsch, Thomas M, primary, Volmer, Léa L., additional, Feisst, Manuel, additional, Bodenbeck, Laura, additional, Hassdenteufel, Kathrin, additional, Le, Thao Vy, additional, Breit, Christiane, additional, Stefanovic, Stefan, additional, Bauer, Armin, additional, Anders, Carolin, additional, Weinert, Lina, additional, Engler, Tobias, additional, Hartkopf, Andreas D., additional, Pfeifer, Nico, additional, Escher, Pascal, additional, Mausch, Marc, additional, Heinze, Oliver, additional, Suetterlin, Marc, additional, Brucker, Sara Y., additional, Schneeweiss, Andreas, additional, and Wallwiener, Markus, additional

Published
2024
Full Text
View/download PDF

27. Update Mammakarzinom 2023 Teil 2 – Brustkrebs in fortgeschrittenen Krankheitsstadien

Author

Lux, Michael P., additional, Hartkopf, Andreas D., additional, Fehm, Tanja N., additional, Welslau, Manfred, additional, Müller, Volkmar, additional, Schütz, Florian, additional, Fasching, Peter A., additional, Janni, Wolfgang, additional, Witzel, Isabell, additional, Thomssen, Christoph, additional, Beierlein, Milena, additional, Belleville, Erik, additional, Untch, Michael, additional, Thill, Marc, additional, Tesch, Hans, additional, Ditsch, Nina, additional, Aktas, Bahriye, additional, Banys-Paluchowski, Maggie, additional, Kolberg-Liedtke, Cornelia, additional, Wöckel, Achim, additional, Kolberg, Hans-Christian, additional, Harbeck, Nadia, additional, Bartsch, Rupert, additional, Schneeweiss, Andreas, additional, Ettl, Johannes, additional, Würstlein, Rachel, additional, Krug, David, additional, Taran, Florin-Andrei, additional, Lüftner, Diana, additional, and Stickeler, Elmar, additional

Published
2023
Full Text
View/download PDF

28. Update Mammakarzinom 2023 Teil 3 – Expertenmeinungen zu Brustkrebs in frühen Krankheitsstadien

Author

Kolberg, Hans-Christian, additional, Hartkopf, Andreas D., additional, Fehm, Tanja N., additional, Welslau, Manfred, additional, Müller, Volkmar, additional, Schütz, Florian, additional, Fasching, Peter A., additional, Janni, Wolfgang, additional, Witzel, Isabell, additional, Thomssen, Christoph, additional, Beierlein, Milena, additional, Belleville, Erik, additional, Untch, Michael, additional, Thill, Marc, additional, Tesch, Hans, additional, Ditsch, Nina, additional, Lux, Michael P., additional, Aktas, Bahriye, additional, Banys-Paluchowski, Maggie, additional, Kolberg-Liedtke, Cornelia, additional, Wöckel, Achim, additional, Harbeck, Nadia, additional, Stickeler, Elmar, additional, Bartsch, Rupert, additional, Schneeweiss, Andreas, additional, Ettl, Johannes, additional, Krug, David, additional, Taran, Florin-Andrei, additional, Lüftner, Diana, additional, and Würstlein, Rachel, additional

Published
2023
Full Text
View/download PDF

31. Klinische Endpunkte in Real-World-Register-Studien: PRAEGNANT-Netzwerk für Patientinnen mit fortgeschrittenem Mammakarzinom

Author

Hartkopf, Andreas D., Emons, Julius, Lux, Michael P., Taran, Florin-Andrei, Overkamp, Friedrich, Tesch, Hans, Titzmann, Adriana, Pöschke, Patrik, Lüftner, Diana, Wallwiener, Markus, Müller, Volkmar, Beckmann, Matthias W., Belleville, Erik, Janni, Wolfgang, Fehm, Tanja N., Kolberg, Hans-Christian, Ettl, Johannes, Wallwiener, Diethelm, Schneeweiss, Andreas, Brucker, Sara Y., and Fasching, Peter A.

Published
2020
Full Text
View/download PDF

33. Soluble NKG2DLs Are Elevated in Breast Cancer Patients and Associate with Disease Outcome.

Author

Seller, Anna, Tegeler, Christian M., Mauermann, Jonas, Schreiber, Tatjana, Hagelstein, Ilona, Liebel, Kai, Koch, André, Heitmann, Jonas S., Greiner, Sarah M., Hayn, Clara, Dannehl, Dominik, Engler, Tobias, Hartkopf, Andreas D., Hahn, Markus, Brucker, Sara Y., Salih, Helmut R., and Märklin, Melanie

Subjects
CANCER patients, KILLER cells, CYTOTOXIC T cells, BREAST cancer, BREAST, CARCINOMA in situ, DUCTAL carcinoma
Abstract

Ligands of the natural killer group 2D (NKG2DL) family are expressed on malignant cells and are usually absent from healthy tissues. Recognition of NKG2DLs such as MICA/B and ULBP1-3 by the activating immunoreceptor NKG2D, expressed by NK and cytotoxic T cells, stimulates anti-tumor immunity in breast cancer. Upregulation of membrane-bound NKG2DLs in breast cancer has been demonstrated by immunohistochemistry. Tumor cells release NKG2DLs via proteolytic cleavage as soluble (s)NKG2DLs, which allows for effective immune escape and is associated with poor prognosis. In this study, we collected serum from 140 breast cancer (BC) and 20 ductal carcinoma in situ (DCIS) patients at the time of initial diagnosis and 20 healthy volunteers (HVs). Serum levels of sNKG2DLs were quantified through the use of ELISA and correlated with clinical data. The analyzed sNKG2DLs were low to absent in HVs and significantly higher in BC patients. For some of the ligands analyzed, higher sNKG2DLs serum levels were associated with the classification of malignant tumor (TNM) stage and grading. Low sMICA serum levels were associated with significantly longer progression-free (PFS) and overall survival (OS). In conclusion, we provide the first insights into sNKG2DLs in BC patients and suggest their potential role in tumor immune escape in breast cancer. Furthermore, our observations suggest that serum sMICA levels may serve as a prognostic parameter in the patients analyzed in this study. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

34. Systemische Therapie von prämenopausalen Patientinnen mit hormonrezeptorpositivem, HER2-negativem Brustkrebs in den Frühstadien – Kontroversen und Standards in der Krankenversorgung.

Author

Müller, Volkmar, Fasching, Peter A., Nabieva, Naiba, Fehm, Tanja N., Thill, Marc, Schmidt, Marcus, Kühn, Thorsten, Banys-Paluchowski, Maggie, Belleville, Erik, Juhasz-Böss, Ingolf, Untch, Michael, Kolberg, Hans-Christian, Harbeck, Nadia, Aktas, Bahriye, Stickeler, Elmar, Kreuzeder, Julia, Hartkopf, Andreas D., Janni, Wolfgang, and Ditsch, Nina

Published
2024
Full Text
View/download PDF

35. Image‐guided metabolomics and transcriptomics reveal tumour heterogeneity in luminal A and B human breast cancer beyond glucose tracer uptake.

Author

Yang, Qianlu, Deng, Sisi, Preibsch, Heike, Schade, Tim‐Colin, Koch, André, Berezhnoy, Georgy, Zizmare, Laimdota, Fischer, Anna, Gückel, Brigitte, Staebler, Annette, Hartkopf, Andreas D., Pichler, Bernd J., la Fougère, Christian, Hahn, Markus, Bonzheim, Irina, Nikolaou, Konstantin, and Trautwein, Christoph

Subjects
TRANSCRIPTOMES, BRCA genes, BREAST cancer, THYMIDYLATE synthase, POSITRON emission tomography, TUMOR classification, PROTON magnetic resonance spectroscopy
Abstract

Background: Breast cancer is a metabolically heterogeneous disease, and although the concept of heterogeneous cancer metabolism is known, its precise role in human breast cancer is yet to be fully elucidated. Methods: We investigated in an explorative approach a cohort of 42 primary mamma carcinoma patients with positron emission tomography/magnetic resonance imaging (PET/MR) prior to surgery, followed by histopathology and molecular diagnosis. From a subset of patients, which showed high metabolic heterogeneity based on tracer uptake and pathology classification, tumour centre and periphery specimen tissue samples were further investigated by a targeted breast cancer gene expression panel and quantitative metabolomics by nuclear magnetic resonance (NMR) spectroscopy. All data were analysed in a combinatory approach. Results: [18F]FDG (2‐deoxy‐2‐[fluorine‐18]fluoro‐d‐glucose) tracer uptake confirmed dominance of glucose metabolism in the breast tumour centre, with lower levels in the periphery. Additionally, we observed differences in lipid and proliferation related genes between luminal A and B subtypes in the centre and periphery. Tumour periphery showed elevated acetate levels and enrichment in lipid metabolic pathways genes especially in luminal B. Furthermore, serine was increased in the periphery and higher expression of thymidylate synthase (TYMS) indicated one‐carbon metabolism increased in tumour periphery. The overall metabolic activity based on [18F]FDG uptake of luminal B subtype was higher than that of luminal A and the difference between the periphery and centre increased with tumour grade. Conclusion: Our analysis indicates variations in metabolism among different breast cancer subtypes and sampling locations which details the heterogeneity of the breast tumours. Correlation analysis of [18F]FDG tracer uptake, transcriptome and tumour metabolites like acetate and serine facilitate the search for new candidates for metabolic tracers and permit distinguishing luminal A and B. This knowledge may help to differentiate subtypes preclinically or to provide patients guide for neoadjuvant therapy and optimised surgical protocols based on individual tumour metabolism. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

37. Update Breast Cancer 2023 Part 3 – Expert Opinions of Early Stage Breast Cancer Therapies

Author

Kolberg, Hans-Christian, additional, Hartkopf, Andreas D., additional, Fehm, Tanja N., additional, Welslau, Manfred, additional, Müller, Volkmar, additional, Schütz, Florian, additional, Fasching, Peter A., additional, Janni, Wolfgang, additional, Witzel, Isabell, additional, Thomssen, Christoph, additional, Beierlein, Milena, additional, Belleville, Erik, additional, Untch, Michael, additional, Thill, Marc, additional, Tesch, Hans, additional, Ditsch, Nina, additional, Lux, Michael P., additional, Aktas, Bahriye, additional, Banys-Paluchowski, Maggie, additional, Kolberg-Liedtke, Cornelia, additional, Wöckel, Achim, additional, Harbeck, Nadia, additional, Stickeler, Elmar, additional, Bartsch, Rupert, additional, Schneeweiss, Andreas, additional, Ettl, Johannes, additional, Krug, David, additional, Taran, Florin-Andrei, additional, Lüftner, Diana, additional, and Würstlein, Rachel, additional

Published
2023
Full Text
View/download PDF

38. Targeting NKG2DL with Bispecific NKG2D–CD16 and NKG2D–CD3 Fusion Proteins on Triple–Negative Breast Cancer

Author

Kaidun, Polina, primary, Holzmayer, Samuel J., additional, Greiner, Sarah M., additional, Seller, Anna, additional, Tegeler, Christian M., additional, Hagelstein, Ilona, additional, Mauermann, Jonas, additional, Engler, Tobias, additional, Koch, André, additional, Hartkopf, Andreas D., additional, Salih, Helmut R., additional, and Märklin, Melanie, additional

Published
2023
Full Text
View/download PDF

39. Treatment landscape of advanced breast cancer patients with hormone receptor positive HER2 negative tumors – Data from the German PRAEGNANT breast cancer registry

Author

Hartkopf, Andreas D., Huober, Jens, Volz, Bernhard, Nabieva, Naiba, Taran, Florin-Andrei, Schwitulla, Judith, Overkamp, Friedrich, Kolberg, Hans-Christian, Hadji, Peyman, Tesch, Hans, Häberle, Lothar, Ettl, Johannes, Lux, Michael P., Lüftner, Diana, Wallwiener, Markus, Müller, Volkmar, Beckmann, Matthias W., Belleville, Erik, Wimberger, Pauline, Hielscher, Carsten, Geberth, Matthias, Fersis, Nikos, Abenhardt, Wolfgang, Kurbacher, Christian, Wuerstlein, Rachel, Thomssen, Christoph, Untch, Michael, Fasching, Peter A., Janni, Wolfgang, Fehm, Tanja N., Wallwiener, Diethelm, Brucker, Sara Y., and Schneeweiss, Andreas

Published
2018
Full Text
View/download PDF

40. Impact of disease progression on health-related quality of life in patients with metastatic breast cancer in the PRAEGNANT breast cancer registry

Author

Müller, Volkmar, Nabieva, Naiba, Häberle, Lothar, Taran, Florin-Andrei, Hartkopf, Andreas D., Volz, Bernhard, Overkamp, Friedrich, Brandl, Anna Lisa, Kolberg, Hans-Christian, Hadji, Peyman, Tesch, Hans, Ettl, Johannes, Lux, Michael P., Lüftner, Diana, Belleville, Erik, Fasching, Peter A., Janni, Wolfgang, Beckmann, Matthias W., Wimberger, Pauline, Hielscher, Carsten, Fehm, Tanja N., Brucker, Sara Y., Wallwiener, Diethelm, Schneeweiss, Andreas, and Wallwiener, Markus

Published
2018
Full Text
View/download PDF

41. Efficacy of neoadjuvant pertuzumab in addition to chemotherapy and trastuzumab in routine clinical treatment of patients with primary breast cancer: a multicentric analysis

Author

Fasching, Peter A., Hartkopf, Andreas D., Gass, Paul, Häberle, Lothar, Akpolat-Basci, Leyla, Hein, Alexander, Volz, Bernhard, Taran, Florin-Andrei, Nabieva, Naiba, Pott, Birgit, Overkamp, Friedrich, Einarson, Hanna, Hadji, Peyman, Tesch, Hans, Ettl, Johannes, Lüftner, Diana, Wallwiener, Markus, Müller, Volkmar, Janni, Wolfgang, Fehm, Tanja N., Schneeweiss, Andreas, Untch, Michael, Pott, Dirk, Lux, Michael P., Geyer, Thomas, Liedtke, Cornelia, Seeger, Harald, Wetzig, Sarah, Hartmann, Arndt, Schulz-Wendtland, Rüdiger, Belleville, Erik, Wallwiener, Diethelm, Beckmann, Matthias W., Brucker, Sara Y., and Kolberg, Hans-Christian

Published
2019
Full Text
View/download PDF

42. Heregulin (HRG) assessment for clinical trial eligibility testing in a molecular registry (PRAEGNANT) in Germany

Author

Huebner, Hanna, Kurbacher, Christian M., Kuesters, Geoffrey, Hartkopf, Andreas D., Lux, Michael P., Huober, Jens, Volz, Bernhard, Taran, Florin-Andrei, Overkamp, Friedrich, Tesch, Hans, Häberle, Lothar, Lüftner, Diana, Wallwiener, Markus, Müller, Volkmar, Beckmann, Matthias W., Belleville, Erik, Ruebner, Matthias, Untch, Michael, Fasching, Peter A., Janni, Wolfgang, Fehm, Tanja N., Kolberg, Hans-Christian, Wallwiener, Diethelm, Brucker, Sara Y., Schneeweiss, Andreas, and Ettl, Johannes

Published
2020
Full Text
View/download PDF

44. Update Breast Cancer 2023 Part 1 – Early Stage Breast Cancer

Author

Hartkopf, Andreas D., additional, Fehm, Tanja N., additional, Welslau, Manfred, additional, Müller, Volkmar, additional, Schütz, Florian, additional, Fasching, Peter A., additional, Janni, Wolfgang, additional, Witzel, Isabell, additional, Thomssen, Christoph, additional, Beierlein, Milena, additional, Belleville, Erik, additional, Untch, Michael, additional, Thill, Marc, additional, Tesch, Hans, additional, Ditsch, Nina, additional, Lux, Michael P., additional, Aktas, Bahriye, additional, Banys-Paluchowski, Maggie, additional, Kolberg-Liedtke, Cornelia, additional, Wöckel, Achim, additional, Kolberg, Hans-Christian, additional, Harbeck, Nadia, additional, Stickeler, Elmar, additional, Bartsch, Rupert, additional, Schneeweiss, Andreas, additional, Ettl, Johannes, additional, Würstlein, Rachel, additional, Krug, David, additional, Taran, Florin-Andrei, additional, and Lüftner, Diana, additional

Published
2023
Full Text
View/download PDF

45. Update Breast Cancer 2023 Part 2 – Advanced-Stage Breast Cancer

Author

Lux, Michael P., additional, Hartkopf, Andreas D., additional, Fehm, Tanja N., additional, Welslau, Manfred, additional, Müller, Volkmar, additional, Schütz, Florian, additional, Fasching, Peter A., additional, Janni, Wolfgang, additional, Witzel, Isabell, additional, Thomssen, Christoph, additional, Beierlein, Milena, additional, Belleville, Erik, additional, Untch, Michael, additional, Thill, Marc, additional, Tesch, Hans, additional, Ditsch, Nina, additional, Aktas, Bahriye, additional, Banys-Paluchowski, Maggie, additional, Kolberg-Liedtke, Cornelia, additional, Wöckel, Achim, additional, Kolberg, Hans-Christian, additional, Harbeck, Nadia, additional, Bartsch, Rupert, additional, Schneeweiss, Andreas, additional, Ettl, Johannes, additional, Würstlein, Rachel, additional, Krug, David, additional, Taran, Florin-Andrei, additional, Lüftner, Diana, additional, and Stickeler, Elmar, additional

Published
2023
Full Text
View/download PDF

46. Systemic Therapy of Premenopausal Patients with Early Stage Hormone Receptor-Positive, HER2-Negative Breast Cancer – Controversies and Standards in Healthcare

Author

Müller, Volkmar, additional, Fasching, Peter A., additional, Nabieva, Naiba, additional, Fehm, Tanja N., additional, Thill, Marc, additional, Schmidt, Marcus, additional, Kühn, Thorsten, additional, Banys-Paluchowski, Maggie, additional, Belleville, Erik, additional, Juhasz-Böss, Ingolf, additional, Untch, Michael, additional, Kolberg, Hans-Christian, additional, Harbeck, Nadia, additional, Aktas, Bahriye, additional, Stickeler, Elmar, additional, Kreuzeder, Julia, additional, Hartkopf, Andreas D., additional, Janni, Wolfgang, additional, and Ditsch, Nina, additional

Published
2023
Full Text
View/download PDF

47. Detection of Disseminated Tumor Cells in Patients with Early Breast Cancer is Associated with 21-Gene-Assay: Results from the Impact of Recurrence Score ® Result on Adjuvant Treatment Decisions and Tumor Cell Dissemination in Estrogen Receptor-Positive and HER2-Negative Patients with Early Breast Cancer (IRMA) Trial

Author

Volmer, Lea L., primary, Dannehl, Dominik, additional, Engler, Tobias, additional, Hahn, Markus, additional, Walter, Christina B., additional, Wallwiener, Markus, additional, Brucker, Sara Y., additional, Taran, Florin-Andrei, additional, and Hartkopf, Andreas D., additional

Published
2023
Full Text
View/download PDF

48. Precision Immunotherapy Utilizing Adapter CAR-T Cells (AdCAR-T) in Metastatic Breast Cancer Leads to Target Specific Lysis.

Author

Önder, Cansu E., Moustafa-Oglou, Moustafa, Schröder, Sarah M., Hartkopf, Andreas D., Koch, André, and Seitz, Christian M.

Subjects
FLOW cytometry, METASTASIS, RESEARCH funding, CELL lines, IMMUNOTHERAPY, BREAST tumors
Abstract

Simple Summary: The development of pleural effusion is a common debilitating occurrence during metastasized breast cancer. Malignant cells in pleural effusions originating from the primary tumor suggest the spread of the disease and can serve as a model for metastatic breast cancer. Hence, we established three-dimensional organoid lines from four patients with malignant pleural effusion. Patient-derived organoids were characterized by flow cytometry for individual target antigen expression profiles. Adapter CAR-T cells (AdCAR-T) and biotinylated monoclonal antibodies were evaluated to specifically target patient-derived organoids and assess responses in a personalized fashion. This study demonstrates the feasibility of precision immunotherapy utilizing AdCAR-T to target patient-individualized antigen patterns. A frequent symptom of metastasized breast cancer (BC) includes the development of malignant pleural effusion (MPE), which contains malignant cells derived from the primary tumor site. The poor prognosis of MPE in metastasized BC indicates the necessity for dependable precision oncology and the importance of models representing the heterogenous nature of metastatic BC. In this study, we cultured MPE-derived metastatic tumor cells from four advanced BC patients using organoid technology. We assessed the expression of tumor-associated antigens on MPE-derived organoid lines by flow cytometry (FC). Based on an individual antigen expression pattern, patient-derived organoids were treated with adapter CAR-T cells (AdCAR-T) and biotinylated monoclonal antibodies targeting CD276, HER2, EGFR, TROP2, or EpCAM. Co-culture assays revealed specific organoid lysis by AdCAR-T depending on individual antigen expression patterns. Our results demonstrate that MPE-derived organoids can serve as a reliable tool for assessing the efficacy of AdCAR-T on metastatic BC in a patient-individualized manner. This approach could potentially be applied in a preclinical setting to instruct therapy decisions. Further, our study demonstrates the feasibility of precision immunotherapy utilizing AdCAR-T to target patient-individualized antigen patterns. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results